|
|
|
09.11.26 - 14:03
|
Delcath Systems Reports Third Quarter 2026 Results and Business Highlights (Business Wire)
|
|
|
Increases 2026 Revenue Guidance to a Range of $115 million to $117 million
Conference Call Today at 8:30 a.m. Eastern TimeQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2026.
Third Quarter 2026 Financial Results
Total revenue of $35.1 million, compared with $20.6 million in the third quarter of 2025
HEPZATO KIT™ revenue of $32.7 million, compared to $19.3 million in the third quarter of 2025
CHEMOSAT® revenue of $2.4 million, compared to $1.3 million in the third quarter of 2025
Gross margins of 89%, compared to 87% in the third quarter of 2025
Net income of $7.0 million, compared to $0.8 million in the third quarter of 2025
Non-GAAP adjusted EBITDA of $11.5 million, compared to $5.3 million in the third quarter of 2025
Cash provided by operations of $8.2 million in the quarter; ...
|
|
|
|
|
26.10.26 - 13:36
|
Delcath Systems to Host Third Quarter 2026 Earnings Call (Business Wire)
|
|
|
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 9, 2026, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2026.
Conference Call Information
To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call.
Event Date: Monday, November 9, 2026
Time: 8:30 AM Eastern Time
Participant Numbers:
Toll Free: 1-800-717-1738
International: 1-646-307-1865
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1773540&tp_key=7840303563A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website here.
About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's...
|
|
|
|
|
11.09.26 - 22:03
|
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either July 2026 or August 2026.
The grants, in the form of Restricted Stock Units (RSUs), totaled 34,000 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan (“Plan”). The RSUs were granted on September 1, 2026 and one-third of the RSUs will vest on the first anniversary of the grant date with the remaining two-thirds of the RSUs vesting in equal annual installments over the following two years. The RSUs are subject to the employee's continued employment with Delcath on each vesting date.
The above-described awards were granted in accor...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.08.26 - 14:03
|
Delcath Systems Reports Second Quarter 2026 Results and Business Highlights (Business Wire)
|
|
|
Increases 2026 Revenue Guidance to a Range of $104M to $108M
Conference Call Today at 8:30 a.m. Eastern TimeQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the second quarter ended June 30, 2026.
Second Quarter 2026 Financial Results
Total revenue of $29.1 million, compared with $24.2 million in the second quarter of 2025
HEPZATO KIT™ revenue of $27.1 million, compared to $22.5 million in the second quarter of 2025
CHEMOSAT® revenue of $2.0 million, compared to $1.7 million in the second quarter of 2025
Gross margins of 90%, compared to 86% in the second quarter of 2025
Net income of $2.7 million for both second quarters in 2026 and 2025
Non-GAAP adjusted EBITDA of $7.6 million, compared to $9.8 million in the second quarter of 2025
Cash provided by operations of $5.7 million in the quarter; compared to $7.3 million i...
|
|
|
|
|
23.07.26 - 22:03
|
Delcath Systems to Host Second Quarter 2026 Earnings Call (Business Wire)
|
|
|
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2026, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2026.
Conference Call Information
To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call.
Event Date: Thursday, August 6, 2026
Time: 8:30 AM Eastern Time
Participant Numbers:
Toll Free: 1-800-717-1738
International: 1-646-307-1865
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1767384&tp_key=cbc23b55c8A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website here.
About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's propr...
|
|
|
16.07.26 - 22:09
|
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either May 2026 or June 2026.
The grants, in the form of Restricted Stock Units (RSUs), totaled 17,000 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan (“Plan”). The RSUs were granted on July 1, 2026 and one-third of the RSUs will vest on the first anniversary of the grant date with the remaining two-thirds of the RSUs vesting in equal annual installments over the following two years. The RSUs are subject to the employee's continued employment with Delcath on each vesting date.
The above-described awards were granted in accordance wi...
|
|
|
15.05.26 - 22:06
|
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either March 2026 or April 2026.
The grants, in the form of Restricted Stock Units (RSUs), totaled 24,500 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan (“Plan”). The RSUs were granted on May 1, 2026 and one-third of the RSUs will vest on the first anniversary of the grant date with the remaining two-thirds of the RSUs vesting in equal annual installments over the following two years. The RSUs are subject to the employee's continued employment with Delcath on each vesting date.
The above-described awards were granted in accordance ...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
